Is Scinai Immunotherapeutics Ltd (SCNI) overvalued? · P/E 0.2, $1.8M cap
Scinai Immunotherapeutics Ltd (SCNI) is a biotechnology company listed on NASDAQ.
This page asks whether Scinai Immunotherapeutics Ltd (SCNI) looks expensive on cached numbers — not a short thesis.
No cached income statement for SCNI, so there is no earnings base to call rich or cheap.
SCNI currently screens at market cap $1.8M and trailing P/E 0.2. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next SCNI 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the SCNI stock page for the full model, not this heading.
Not investment advice.